JP2025512583A - 3-((1R,3R)-1-(2,6-ジフルオロ-4-((1-(3-フルオロプロピル)アゼチジン-3-イル)アミノ)フェニル)-3-メチル-1,3,4,9-テトラヒドロ-2H-ピリド[3,4-b]インドール-2-イル)-2,2-ジフルオロプロパン-1-オール酒石酸塩の固体形態 - Google Patents

3-((1R,3R)-1-(2,6-ジフルオロ-4-((1-(3-フルオロプロピル)アゼチジン-3-イル)アミノ)フェニル)-3-メチル-1,3,4,9-テトラヒドロ-2H-ピリド[3,4-b]インドール-2-イル)-2,2-ジフルオロプロパン-1-オール酒石酸塩の固体形態 Download PDF

Info

Publication number
JP2025512583A
JP2025512583A JP2024562812A JP2024562812A JP2025512583A JP 2025512583 A JP2025512583 A JP 2025512583A JP 2024562812 A JP2024562812 A JP 2024562812A JP 2024562812 A JP2024562812 A JP 2024562812A JP 2025512583 A JP2025512583 A JP 2025512583A
Authority
JP
Japan
Prior art keywords
solution
pharmaceutical composition
formula
filler
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512583A5 (cg-RX-API-DMAC10.html
Inventor
ハオ ホウ,
ラウラ ジャーク,
マイケル カンマーラー,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2025512583A publication Critical patent/JP2025512583A/ja
Publication of JP2025512583A5 publication Critical patent/JP2025512583A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024562812A 2022-04-28 2023-04-27 3-((1R,3R)-1-(2,6-ジフルオロ-4-((1-(3-フルオロプロピル)アゼチジン-3-イル)アミノ)フェニル)-3-メチル-1,3,4,9-テトラヒドロ-2H-ピリド[3,4-b]インドール-2-イル)-2,2-ジフルオロプロパン-1-オール酒石酸塩の固体形態 Pending JP2025512583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22170407 2022-04-28
EP22170407.5 2022-04-28
PCT/EP2023/061060 WO2023209062A1 (en) 2022-04-28 2023-04-27 Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate

Publications (2)

Publication Number Publication Date
JP2025512583A true JP2025512583A (ja) 2025-04-17
JP2025512583A5 JP2025512583A5 (cg-RX-API-DMAC10.html) 2026-05-07

Family

ID=81392840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562812A Pending JP2025512583A (ja) 2022-04-28 2023-04-27 3-((1R,3R)-1-(2,6-ジフルオロ-4-((1-(3-フルオロプロピル)アゼチジン-3-イル)アミノ)フェニル)-3-メチル-1,3,4,9-テトラヒドロ-2H-ピリド[3,4-b]インドール-2-イル)-2,2-ジフルオロプロパン-1-オール酒石酸塩の固体形態

Country Status (11)

Country Link
US (1) US20250282775A1 (cg-RX-API-DMAC10.html)
EP (1) EP4514792A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025512583A (cg-RX-API-DMAC10.html)
KR (1) KR20250006222A (cg-RX-API-DMAC10.html)
CN (1) CN119156386A (cg-RX-API-DMAC10.html)
AU (1) AU2023262166A1 (cg-RX-API-DMAC10.html)
CA (1) CA3255956A1 (cg-RX-API-DMAC10.html)
IL (1) IL316096A (cg-RX-API-DMAC10.html)
MX (1) MX2024013116A (cg-RX-API-DMAC10.html)
TW (1) TW202400141A (cg-RX-API-DMAC10.html)
WO (1) WO2023209062A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250319032A1 (en) * 2024-04-15 2025-10-16 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
US20220380348A1 (en) * 2019-10-04 2022-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations

Also Published As

Publication number Publication date
CN119156386A (zh) 2024-12-17
TW202400141A (zh) 2024-01-01
IL316096A (en) 2024-12-01
EP4514792A1 (en) 2025-03-05
WO2023209062A1 (en) 2023-11-02
MX2024013116A (es) 2024-11-08
CA3255956A1 (en) 2023-11-02
US20250282775A1 (en) 2025-09-11
KR20250006222A (ko) 2025-01-10
AU2023262166A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
KR101830147B1 (ko) 벤다무스틴의 경구 투약 형태 및 그것의 치료 용도
JP4757872B2 (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
JP4633469B2 (ja) 経口固形医薬
AU2015265542B2 (en) Improved forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
JP4805234B2 (ja) 経口固形医薬
JP2025169294A (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
EP3354283B1 (en) Pharmaceutical capsule composition comprising silodosin
KR20120098878A (ko) 용출 안정성 제제
US20250282775A1 (en) Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
KR20050010886A (ko) 바제독시펜 치료 방식
CN109001353B (zh) 富马酸喹硫平片剂药物组合物和制法
WO2025054280A1 (en) Formulations of stat3 inhibitors and methods of use thereof
CN118574622B (zh) Senaparib和替莫唑胺的复方制剂及其制备方法
HK40115442A (en) Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
JP6669937B2 (ja) 5−ht6拮抗薬の医薬組成物
JP2023516358A (ja) キナーゼ阻害剤の医薬組成物
CA3059180C (en) Sustained release compositions of 4-aminopyridine
JP2024539060A (ja) 医薬組成物
WO2025242217A1 (zh) 一种含噻吩并嘧啶化合物的药物组合物、其制备方法及用途
RU2024129716A (ru) ТВЕРДАЯ ФОРМА ТАРТРАТА 3-((1R,3R)-1-(2,6-ДИФТОР-4-((1-(3-ФТОРПРОПИЛ)АЗЕТИДИН-3- ИЛ)АМИНО)ФЕНИЛ)-3-МЕТИЛ-1,3,4,9-ТЕТРАГИДРО-2H-ПИРИДО[3,4-b]ИНДОЛ-2-ИЛ)-2,2- ДИФТОРПРОПАН-1-ОЛА
TW200817390A (en) Compositions, kits and methods of a titration schedule for bifeprunox compounds
TW201729805A (zh) 一種含有咪唑啉類衍生物的醫藥組成物
HK1107768B (en) Solid drug for oral use
HK1244703B (en) Pharmaceutical composition containing imidazoline derivative
HK1260334A1 (en) Sustained release compositions of 4-aminopyridine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260423